GSE196035 GSE196037 MEN1 inhibition 3 v 11 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE196035_GSE196037_MEN1 inhibition_3_v_11_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE196035_GSE196037_MEN1 inhibition_3_v_11_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE196035_GSE196037_MEN1 inhibition_3_v_11_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE196035_GSE196037_MEN1 inhibition_3_v_11_human_up.

Results found

Linked to

 

Label

Description

 

Gene

OSER1 divergent transcript

Gene

uncharacterized LOC643977

Gene

RAB6C antisense RNA 1

Gene

long intergenic non-protein coding RNA 2475

Gene

uncharacterized LOC105371899

Gene

uncharacterized LOC442497

Gene

RNA, U5B small nuclear 1

Gene

long intergenic non-protein coding RNA 408

Gene

uncharacterized LOC105373244

Gene

uncharacterized LOC107986768

  • Gene

    OSER1 divergent transcript


  • Gene

    uncharacterized LOC643977


  • Gene

    RAB6C antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 2475


  • Gene

    uncharacterized LOC105371899


  • Gene

    uncharacterized LOC442497


  • Gene

    RNA, U5B small nuclear 1


  • Gene

    long intergenic non-protein coding RNA 408


  • Gene

    uncharacterized LOC105373244


  • Gene

    uncharacterized LOC107986768

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.